British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's
disease and ulcerative colitis.
The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape".
AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.
AbbVie will stop funding the drug's development, AstraZeneca said.
AbbVie's Skyrizi also treats Crohn's disease.
The Community Pharmacist Consultation Service (CPCS) will be expanded to enable urgent and emergency care settings to refer patients to a community pharmacist
for a consultation for minor illness or urgent medicine supply from Monday (15 May), the DHSC and NHSE said.
The service builds on the progress made in GP referrals via the CPCS and hospital referrals under the Discharge Medicine Service. It was originally planned to launch
in March, and fee for this service will be the existing CPCS fee of £14, as per the agreement for both year 4 and year 5 of the Community Pharmacy Contractual
Framework (CPCF) 2019 to 2024 5-year deal.
In an update on the CPCF, published today (12 May), the Department of Health and Social Care (DHSC) and NHS England (NHSE) has also committed to the 4 October 2023
launch date for the Tier 2 of the Pharmacy Contraception Service, subject to a positive evaluation of the pilot.
The Tier 1 of the service was launched on 24 April, delayed by over three months. This new service enables community pharmacists to provide ongoing management, via
a patient group direction (PGD), of routine oral contraception that was initiated in general practice or by a sexual health clinic. The fees for this service are as
follows: a fee for each consultation of £18; and a set-up fee of £900, paid in instalments.
The Tier 2 will "enable community pharmacists to also initiate oral contraception, via a PGD, and provide ongoing clinical checks and annual reviews," Alette Addison,
deputy director for pharmacy, dental and optical at the DHSC and Ali Sparke, director for dentistry, community pharmacy and optometry at the NHSE, said in a letter.
Community Pharmacy England (CPE) to host a Parliamentary drop-in event in July to brief MPs and Peers about the ongoing medicines supply chain issues that
are negatively affecting pharmacies and their patients across the country.
CPE's Pressures Survey earlier this year highlighted the extent of both the operational and financial impacts of medicines supply issues on pharmacy businesses,
therefore it has continued to hear from both pharmacy owners and others about the problems.
The event aims to ensure that MPs understand the problems and their impact on pharmacies.
Peter Dowd MP is hosting the event, joined by representatives from Community Pharmacy England, the Nuffield Trust, patient groups and more.
The event will also be another opportunity to talk to MPs from across the political spectrum about the very serious situation that community pharmacies still find
themselves in and the need for further investment in the sector.
Janet Morrison OBE, Chief executive of Community Pharmacy England said: "The results of our Pressures Survey earlier this year showed just how much supply issues
are continuing to negatively impact pharmacy businesses and all those who work in them. The survey found that almost all pharmacy owners (97%) are facing
significant increases in wholesaler and medicine supply issues, with 71% saying this was leading to delays in prescriptions being issued.
In a long scripted overhaul of its business, GlaxoSmithKline spun off its consumer health business on Monday (July 18) in the biggest listing in Europe for
more than a decade.
The new company, Haleon, becomes the world's biggest standalone consumer health business, home to brands including Sensodyne toothpaste, pain relief drug Panadol
and cold treatment Theraflu.
Shares in Haleon started trading at 330 pence on Monday morning, giving the business a market valuation of around £30.5 billion - dashing high hopes for Haleon's
much higher market valuation after GSK in January said it had rebuffed a £50 billion offer from Unilever on the basis it was too low.
The major strategy shift by GSK chief executive Emma Walmsley to focus on the company's core pharmaceuticals business comes after she faced intense activist
shareholder pressure over its delays in producing Covid jabs and treatments.
The Pharmacist' Defence Association (PDA) has welcomed the General Pharmaceutical Council (GPhC) and the Pharmaceutical Society of Northern Ireland (PSNI)'s
plan to ensure a more robust, fair and positive experience for trainees, provisionally registered and potential pharmacists who will be sitting the November 2022
assessment.
"Many candidates at the latest (June 2022) assessment experienced significant delays, technical issues, inadequate invigilation, and disturbances in test centres
around the UK as the newly appointed company BTL ran the high-stakes pharmacist examinations for the first time. The next online exam is due in November 2022 and the
PDA welcome proposed improvements to be introduced before that sitting," said the association.
For some, provisional registration was the accepted response from the GPhC, but for others, such as potential pharmacists who did not want the provisional role,
those unable to find a suitable provisional post, or some that did not meet the criteria for provisional registration, they found themselves in financial
difficulties through no fault of their own, having reasonably expected to have joined the register in the Summer.
Healthcare workers, including community pharmacy staff, can book their Covid-19 booster vaccination through the National Booking Service from Wednesday
(September 7) onwards.
NHS England has announced that around seven million people, including those aged 75 and over, people who are immunosuppressed and health and care workers will be
able to book an appointment for their Covid-19 booster vaccinations online or by calling 119.
Eligible staff are encouraged to book an appointment for a booster dose as soon as possible, provided it has been at least three months since their last dose of the
vaccine.
"For other eligible patients (not health and care workers), invitations are being sent out and will be landing on their doormats from Wednesday 7th September
inviting people to book their appointment for the following week without delay. The NHS will contact people when it is their turn to book in for the vaccine -
there will be no need for patients to contact the NHS," said PSNC.
70 per cent of community pharmacies still waiting for government nod to start Covid booster jabdesc-Nearly 70 per cent of community pharmacies in England that offered to participate in the Covid-19 booster programme are still waiting for approval or have
been refused, ministers admitted on Monday (December 13).
The Liberal Democrats' health spokesperson, Daisy Cooper, exposed the low approval rate and long delays through a written parliamentary question to the health secretary as to "how many community pharmacies were providing Covid-19 vaccinations as of 3 December 2021."In response vaccines minister Maggie Throup said: "As of the end of September 2021, 4,733 contractors submitted 5,376 expressions of interest to take part in the booster vaccination programme, with 1,454 accepted."She added: "As of 3 December 2021, 1,336 community pharmacy vaccination sites were actively providing the service."
Some applications were decided by NHS England rather than the Department of Health and Social Care (DHSC).
Attempts to deal with record waiting lists for hospital treatment caused by the Covid-19 pandemic are at risk of being derailed by a staffing crisis, which is being exacerbated by the Omicron wave, a cross-party lawmakers' report said on Thursday (January 6).
The report entitled 'Clearing the backlog caused by the pandemic' calls for a broader national health and care recovery plan - one that would embrace A&E, mental health, GPs, community and social care.
Hospitals are facing extreme pressure as they try to catch up on months of operations that have been delayed and suspended during the pandemic, as Covid-19 hospitalizations rise once more and self-isolation hits staffing levels.
There is a record 5.8 million waiting list for elective care, the Health and Social Care Committee said, adding that a recent surge in the Omicron variant has pushed cases to record highs and intensified pre-existing issues.
NHS chief executive Amanda Pritchard today (March 1) announced a new campaign to promote early detection of cancer, when it is easier to treat.
The campaign, which would run across TV, radio, and social media from Wednesday (March 2), is the first to focus on tackling the fear of cancer rather thanspecific symptoms.
It is in line with the NHS Long Term Plan's commitment to increase cancer detection at an early stage by 2028.
As per the NHS figures, the number of people getting checked for cancer increased by over half a million between December 2020 and December 2021.
Speaking ahead of the launch, Pritchard, said: "We know that the prospect of a cancer diagnosis can be daunting for people and that is exactly why we are launching this potentially lifesaving campaign - we want to allay people's fear about cancer and encourage them to get checked without delay.
The Department of Health and Social Care (DHSC) has published plans to amend current pharmacy legislation on dispensing errors and clarify how registered
pharmacies are governed.
The Department's response to a public consultation on rebalancing medicines legislation and pharmacy regulation programme first proposed in summer 2018 was
delayed due to Brexit and the Covid-19 pandemic.
The programme aims to clarify and strengthen the organisational governance arrangements of registered pharmacies, specifically to define and clarify the core
purpose of the Responsible Pharmacist and Superintendent Pharmacist roles.
It will also give the General Pharmaceutical Council (GPhC) powers to define in professional standards how those roles are fulfilled.
The recruitment of pharmacists in Primary Care Networks (PCNs) has exacerbated a general shortage of pharmacists, revealed an independent review of Integrated
Care Systems (ICSs) published on Tuesday (4 April).
The review, Rt Hon Patricia Hewitt, highlighted the impact that the Additional Roles Reimbursement Scheme (ARRS) roles for pharmacists are having on the community
pharmacy sector.
"Contracts with national requirements can have unintended consequences when applied to particular circumstances. For instance, the national requirements and funding
of Additional Roles Reimbursement Scheme (ARRS) roles for community pharmacists within PCNs, has on occasion exacerbated the problem of a general shortage of
pharmacists, with some now preferring to work within primary care rather than remain in community pharmacies or acute hospitals, compounding the problem of community
pharmacy closures and delayed discharges."
It set out to consider the oversight and governance of ICS in England and the NHS targets and priorities for which Integrated Care Boards (ICBs) are accountable,
including those set out in the Government's mandate to NHS England.
As part of this work, Hewitt and her team engaged with a wide range of stakeholders representing various local health and social care settings, including LPCs.
The Royal Pharmaceutical Society (RPS) has urged the government to amend medicines legislation to allow pharmacists to make minor amendments to a prescription
without any protocol being needed.
RPS wants to see a change in the law that makes the whole process of supply of medicines easier and quicker, enabling pharmacists to use their knowledge and expertise
in medicines to better support patients.
"At present a prescription can only be changed by a prescriber, which causes unnecessary workload for GPs and delays for patients," said RPS.
RPS President Professor Claire Anderson said: "We want to see all pharmacists across the UK able to supply a different quantity, strength or formulation of a medicine
(for example changing capsules to tablets) when required, to avoid unnecessary bureaucracy and the need for an SSP to be developed, signed and authorised by a
Minister. In effect it would mean that pharmacists can help patients straight away - it would future proof the problem to some degree.
harmacists in the town of Barnoldswick in Lancashire are reportedly suffering from various problems including a lack of medicines and the movement or loss
of pharmacy staff.
Problems, including delays with supply of insulin, were reported at a recent Pendle Council West Craven meeting.
And this week the head of one pharmacy chain, Whitworth, highlighted a range of issues faced by his teams including supply chains, costs, loss of staff and NHS
reimbursement for contractors.
In Barnoldswick, queues have formed inside and outside pharmacies as people attempt to get prescriptions. Some said they had to wait for days to get what they
needed, had made repeat-visits to pharmacies and were unsure when medicines might arrive.
They also said the number of pharmacies in the area have fallen over the years.
Two town centre pharmacies, Whitworth and Well, are located opposite each other, close to a doctors' surgery. Standing in one queue outside Whitworth was Marilyn
King.
She said: "I have been waiting seven days to get my prescription for blood pressure and some other medicines. This week, I've come back time after time. But the
staff say sorry, they have not got it in because nobody has delivered it.
"I came here on Saturday, when there was a queue. But the pharmacist was not here. I came again on Tuesday and then Wednesday. Then finally, just when I reached
the front of the queue, they asked me to come back in an hour…
Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure.
The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection
in pre-filled pen will be out of stock from early May until mid-July 2024.
"The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations," it said.
However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024.
Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.
Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential
bias in the design and use of medical devices.
Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three
areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics.
The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood
oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen
levels in such patients were missed.
However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care.
Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin
tones within the NHS and eliminating racial bias from data sets employed in clinical studies.
The latest findings from the National Cancer Patient Experience Survey 2022 by QualityWatch, a joint programme with the Nuffield Trust and the Health
Foundation shed light on concerning disparities faced by ethnic minority communities in the UK healthcare system.
Despite strides in cancer care, the survey highlights persistent challenges in easy and equitable access to timely diagnosis and quality communication,
particularly for individuals from Mixed, Black, or Asian backgrounds.
Key insights from the survey underscored that individuals from ethnic minority groups often require a higher number of interactions with healthcare professionals
before receiving a cancer diagnosis.
Notably, one in three people from Mixed, Black, or Asian ethnicities needed three or more visits to a GP practice, compared to the average of one in five across
the population.
These delays in diagnosis can have significant implications for treatment outcomes and overall patient experience.
Moreover, the survey revealed concerning trends regarding the quality of communication following a cancer diagnosis among ethnic minority patients.
In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions.
The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From
non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns.
This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also
how we feel about ourselves.
Botox Injections
Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial
muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the
forehead, crow's feet, and frown lines between the brows.
The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com
note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine
lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.
Poverty not only takes a significant toll on people's health but also leads to additional costs for the National Health Service (NHS). Rise in deep poverty,
cost-of-living crisis, and high pressure on NHS services have worsened the situation, according to a study published by The King's Fund this week.
The report underscored that poverty and deprivation contribute to a greater prevalence of diseases, difficulties in accessing health care, late or delayed
treatment, and worse health outcomes. These challenges could be seen across various NHS services, spanning from emergency care to dental services
Additionally, it revealed that 30 per cent of people living in the most deprived areas have turned to 999, 111, A&E or a walk-in centre because they could not
access a GP appointment.
In 2016, the Joseph Rowntree Foundation (JRF) estimated the cost of poverty on health care at £29 billion (£34 billion in current prices). As the proportion of
people living in deep poverty has risen, the situation has worsened. In 2021/22, six million people were living in very deep poverty, up from 4.5 million two
decades ago. Currently, more than one in five people in the UK are estimated to be living in poverty, the report noted.
Deprivation is linked to a range of diet-related health problems, including cardiovascular disease and diabetes, as well as mental illness. According to the
report, the depression rate is two times higher among people living in the most deprived areas, compared to the least deprived areas.
Expressing apprehension over the concerning decline in the nursing workforce, Sir Julian Hartley, CEO of NHS Providers, urged the forthcoming government
to bolster investment in nursing education and enhance support for student nurses.
Recent analysis from the Royal College of Nursing (RCN) has projected that the NHS Long Term Workforce Plan will fall short by 10,000 new nurses by 2025.
Commenting on the RCN analysis, Sir Hartley underscored the critical importance of having an adequate number of nurses to ensure the delivery of safe,
high-quality patient care.
"Without enough nurses, the delivery of safe, high-quality patient care is compromised," he said.
He cautioned that the predicted shortfall in nurses would exacerbate existing pressures on the NHS, resulting in long waiting times, delayed treatments and
staff burnout.
Long appointment wait times, embarrassment, and lack of trust are causing thousands of Brits to avoid visiting doctors, according to new research by
Newfoundland Diagnostics.
With 1 in 4 individuals resorting to A&E due to the lack of available GP appointments, which adds to the NHS burden, the medical self-testing brand believes that
educating the nation on at-home testing can help ease the strain on the health service.
The research revealed the top five reasons why Brits avoid visiting doctors for medical testing:
Appointments taking too long to book (28 per cent)
Embarrassment around their illnesses (15 per cent)
Preference for at-home testing (12 per cent)
Not having time (10 per cent)
Lack of trust in the NHS or their GP (7 per cent)
The research team cautioned that delaying care can worsen conditions, resulting in more severe cases that place greater strain on the NHS.